

Galliprant 20 mg - Tablet

Authorised

- Grapiprant

Product identification

Medicine name:

Galliprant 20 mg - Tablet

Active substance:

Grapiprant

Target species:

Dog

Route of administration:

Oral use

Product details

Active substance and strength:

Grapiprant

20.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:

Tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QM01AX

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Available in:

Austria , Belgium , Czechia , Denmark , Finland , France , Germany , Hungary , Ireland , Italy , Luxembourg , Netherlands , Norway , Poland , Portugal , Romania , Spain , Sweden , United Kingdom (Northern Ireland)

Package description:

Packaging: Bottle (HDPE), Package_size: 30 tablets

Packaging: Bottle (HDPE), Package_size: 7 tablets

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Elanco GmbH

Marketing authorisation date:

9/01/2018

Manufacturing sites for batch release:

Elanco France S.A.S.

Responsible authority:

European Commission

Authorisation number:

This information is not available for this product.

Date of authorisation status change:

9/01/2018

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 11/01/2024

[Download](#)

ema-puar-galliprant-v-4222-par-en.pdf